- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00173238
The Study of Human Atherosclerosis by Polarization-Sensitive Optical Coherence Tomography
Atherosclerosis is unquestionably the leading cause of morbidity and mortality in developed countries, and the world-wide importance of acute vascular syndromes is increasing. Rupture of atherosclerotic plaque has been identified as the proximate event in the majority of cases of acute ischemic syndromes. Therefore, modalities capable of characterizing the atherosclerotic lesion may be helpful in understanding its natural history and detecting lesions with high risk for acute events.
Optical coherence tomography (OCT) is a powerful tool capable of tomographic imaging based on low coherence interferometry. It is analogous to ultrasound imaging except that it uses infrared light instead of sound. Polarization-sensitive optical coherence tomography (PS-OCT) combines the advantages of OCT with additional image contrast of the sample. The added contrast is based on the ability of PS-OCT to detect the birefringent properties of a sample (phase retardation and fast-axis orientation) simultaneously.
The goals of this project are: 1) to examine whether PS-OCT is an acceptable tool for the characterization of typical plaque constituents; and 2) to explain the correlation between birefringence and forming or rupture of a plaque; and 3) to establish a quantitative PS-OCT image criteria for atherosclerotic plaque characterization in vitro.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment
Contacts and Locations
Study Contact
- Name: Nai-Kuan Chou, MD.,PhD
- Phone Number: 5066 886-2-23123456
- Email: nickchou@ha.mc.ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Nai-Kuan Chou, MD.,PhD
- Phone Number: 5066 886-2-23123456
- Email: nickchou@ha.mc.ntu.edu.tw
-
Principal Investigator:
- Nai-Kuan Chou, MD.,PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Heart transplantation, atherosclerosis
Exclusion Criteria:
- Infection
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Investigators
- Principal Investigator: Nai-Kuan Chou, MD.,PhD, National Taiwan University Hospital,Taipei.Taiwan
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9461700533
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pathological Conditions, Anatomical
-
Assistance Publique - Hôpitaux de ParisAgence Regionale de Sante d'Ile de FranceCompletedAnatomical Pathological ConditionFrance
-
Sisli Hamidiye Etfal Training and Research HospitalBartin State HospitalCompletedAnatomical Pathological Condition | Prolapse GenitalTurkey
-
Abant Izzet Baysal UniversityRecruitingEducational Problems | Anatomical Pathological ConditionTurkey
-
University of Missouri-ColumbiaMayo Clinic; Washington University School of Medicine; University Hospitals Cleveland...TerminatedHernia | Pathological Conditions, Signs and SymptomsUnited States
-
Federal University of Health Science of Porto AlegreIrmandade Santa Casa de Misericórdia de Porto AlegreUnknownGynecologic Cancer | Pathological ConstrictionBrazil
-
Shouldice HospitalRecruiting
-
Universidade Federal do Rio de JaneiroRecruiting
-
Western University, CanadaCosm Medical Corp.Active, not recruiting
-
Universitaire Ziekenhuizen KU LeuvenActive, not recruiting
-
Padagis LLCImpax Laboratories, LLCCompleted